NASDAQ:AXON - Axovant Sciences Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$2.42 -0.05 (-2.02 %)
(As of 07/18/2018 12:36 PM ET)
Previous Close$2.48
Today's Range$2.38 - $2.50
52-Week Range$1.02 - $27.98
Volume17,763 shs
Average Volume3.58 million shs
Market Capitalization$265.16 million
P/E Ratio-1.17
Dividend YieldN/A
Beta-0.12
Axovant Sciences logoAxovant Sciences Ltd., a clinical-stage biopharmaceutical company, engages in developing and commercializing medicines for the treatment of dementia and related neurological disorders in the United States and Europe. Its lead product candidate, intepirdine, a selective 5-HT6 receptor antagonist, which is in Phase III clinical trial for the treatment of Alzheimer's disease; in Phase IIb clinical trial for treating dementia with Lewy bodies (DLB); and in Phase II clinical trial for treating cait and balance in Alzheimer's disease, DLB, and Parkinson's disease dementia. The company is also developing nelotanserin, a selective 5-HT2A receptor inverse agonist, which is in Phase II clinical trial for the treatment of visual hallucinations in patients with Lewy body dementia (LBD) and REM behavior disorder in patients with LBD. In addition, it focuses on developing RVT-103, a combination of donepezil and a peripheral muscarinic receptor antagonist; and RVT-104, a combination of rivastigmine and a peripheral muscarinic receptor antagonist as treatments for patients with Alzheimer's disease or DLB. The company was formerly known as Roivant Neurosciences Ltd. and changed its name to Axovant Sciences Ltd. in March 2015. The company was founded in 2014 and is based in London, the United Kingdom. Axovant Sciences Ltd. is a subsidiary of Roivant Sciences Ltd.

Receive AXON News and Ratings via Email

Sign-up to receive the latest news and ratings for AXON and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:AXON
CUSIPN/A
Phone44-20-3318-9708

Debt

Debt-to-Equity Ratio0.60
Current Ratio3.40
Quick Ratio3.40

Price-To-Earnings

Trailing P/E Ratio-1.17
Forward P/E Ratio-1.61
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$0.66 per share
Price / Book3.67

Profitability

EPS (Most Recent Fiscal Year)($2.06)
Net Income$-221,570,000.00
Net MarginsN/A
Return on Equity-164.96%
Return on Assets-97.15%

Miscellaneous

Employees45
Outstanding Shares107,790,000
Market Cap$265.16

The Truth About Cryptocurrencies

Axovant Sciences (NASDAQ:AXON) Frequently Asked Questions

What is Axovant Sciences' stock symbol?

Axovant Sciences trades on the NASDAQ under the ticker symbol "AXON."

How were Axovant Sciences' earnings last quarter?

Axovant Sciences Ltd (NASDAQ:AXON) issued its earnings results on Monday, June, 11th. The biotechnology company reported ($0.23) earnings per share for the quarter, topping the Zacks' consensus estimate of ($0.34) by $0.11. View Axovant Sciences' Earnings History.

When is Axovant Sciences' next earnings date?

Axovant Sciences is scheduled to release their next quarterly earnings announcement on Monday, August, 6th 2018. View Earnings Estimates for Axovant Sciences.

What price target have analysts set for AXON?

10 brokerages have issued twelve-month price objectives for Axovant Sciences' stock. Their forecasts range from $4.00 to $30.00. On average, they expect Axovant Sciences' stock price to reach $13.1111 in the next twelve months. This suggests a possible upside of 444.0% from the stock's current price. View Analyst Ratings for Axovant Sciences.

What is the consensus analysts' recommendation for Axovant Sciences?

10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Axovant Sciences in the last year. There are currently 7 hold ratings and 3 buy ratings for the stock, resulting in a consensus recommendation of "Hold."

What are Wall Street analysts saying about Axovant Sciences stock?

Here are some recent quotes from research analysts about Axovant Sciences stock:
  • 1. According to Zacks Investment Research, "Axovant Sciences Ltd. is a biopharmaceutical company which focuses on the acquisition, development and commercialization of therapeutics for the treatment of neurodegenerative disorders. Its product candidate includes RVT-101 which is in different clinical trial for the treatment of Alzheimer's disease and other forms of dementia. Axovant Sciences Ltd. is based in Hamilton, Bermuda. " (7/12/2018)
  • 2. HC Wainwright analysts commented, "We believe the licensing agreement with the exclusive worldwide rights to develop and commercialize AXO- Lenti-PD marks the rebirth of Axovant as a pioneering GT company in the CNS space. As a novel approach, GT has shown promising potentials in Parkinson’s disease (PD), and we believe lentiviral vectors may be particularly suited for PD as compared to AAV-mediated gene delivery methods (discussed below). With the recent management restructuring to include industry veterans in the GT space, the leading lentiviral therapy technologies from the strong in-house expertise in the CNS space, Axovant has undertaken a bold and measured transformation that sets the tone for future optionality beyond PD, and should engage new investors who are interested in the intersection between GT and CNS spaces, in our view." (6/7/2018)
  • 3. Chardan Capital analysts commented, "We now assign an incremental $2/share of value to AXON based on AXON capturing some of this value. We expect Oxford BioMedica striking new partnerships in the GT space will provide further upside to shares from here. We note that Axovant has strengthened its management with the addition of gene therapy experts to its leadership. Axovant announced the addition of Dr. Michael Hayden as Chairman of its SAB. Dr. Hayden “played a key role in the discovery and development of Glybera”. With this deal, Axovant announced its new CTO will be Dr. Fraser Wright, the co-founder and former CTO of Spark Therapeutics (Buy)." (6/6/2018)
  • 4. Cowen Inc analysts commented, "We maintain our BUY rating and $25 PT for SVRA shares." (2/13/2018)

Are investors shorting Axovant Sciences?

Axovant Sciences saw a increase in short interest in June. As of June 15th, there was short interest totalling 5,144,083 shares, an increase of 111.9% from the May 31st total of 2,427,822 shares. Based on an average trading volume of 25,625,825 shares, the short-interest ratio is currently 0.2 days. Currently, 29.0% of the shares of the stock are short sold. View Axovant Sciences' Current Options Chain.

Who are some of Axovant Sciences' key competitors?

Who are Axovant Sciences' key executives?

Axovant Sciences' management team includes the folowing people:
  • Dr. Gregory M. Weinhoff, Chief Financial Officer (Age 47)
  • Dr. Pavan Cheruvu, Chief Exec. Officer
  • Mr. Michael Adasczik, Principal Accounting Officer (Age 44)
  • Mr. Jonathan Neely, Head of Investor Relations & Corp. Communications
  • Ms. Marianne L. Romeo Dinsmore, Head of Global Transactions & Risk Management (Age 50)

When did Axovant Sciences IPO?

(AXON) raised $251 million in an IPO on Thursday, June 11th 2015. The company issued 17,900,000 shares at $13.00-$15.00 per share. Jefferies, Evercore ISI and RBC Capital Markets acted as the underwriters for the IPO and JMP Securities and Baird were co-managers.

Has Axovant Sciences been receiving favorable news coverage?

News coverage about AXON stock has trended somewhat positive recently, according to Accern Sentiment Analysis. Accern identifies negative and positive news coverage by analyzing more than 20 million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Axovant Sciences earned a media sentiment score of 0.13 on Accern's scale. They also assigned press coverage about the biotechnology company an impact score of 44.54 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock's share price in the next few days.

Who are Axovant Sciences' major shareholders?

Axovant Sciences' stock is owned by many different of retail and institutional investors. Top institutional shareholders include DEXXON HOLDINGS LTD. (73.10%), LO ANDREW (73.10%), QVT FINANCIAL LP (73.10%), SVF INVESTMENTS (UK) LTD (73.10%), VIKING GLOBAL INVESTORS LP (73.10%) and MACHADO PATRICK (73.10%). Company insiders that own Axovant Sciences stock include David Hung, George Bickerstaff, Global Investors Lp Viking and W Anthony Vernon. View Institutional Ownership Trends for Axovant Sciences.

How do I buy shares of Axovant Sciences?

Shares of AXON can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Axovant Sciences' stock price today?

One share of AXON stock can currently be purchased for approximately $2.41.

How big of a company is Axovant Sciences?

Axovant Sciences has a market capitalization of $265.16 million. The biotechnology company earns $-221,570,000.00 in net income (profit) each year or ($2.06) on an earnings per share basis. Axovant Sciences employs 45 workers across the globe.

How can I contact Axovant Sciences?

Axovant Sciences' mailing address is 20-22 BEDFORD ROW, LONDON X0, WC1R 4JS. The biotechnology company can be reached via phone at 44-20-3318-9708.


MarketBeat Community Rating for Axovant Sciences (NASDAQ AXON)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  260 (Vote Outperform)
Underperform Votes:  269 (Vote Underperform)
Total Votes:  529
MarketBeat's community ratings are surveys of what our community members think about Axovant Sciences and other stocks. Vote "Outperform" if you believe AXON will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AXON will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 7/18/2018 by MarketBeat.com Staff

Featured Article: Analyst Ratings

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.